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Abstract: Age-related muscle wasting can compromise functional abilities of the elderly. Protein in-
take stimulates muscle protein synthesis; however, ageing muscle is more resistant to stimuli.
This double-blinded, randomized, controlled trial is one of the first registered studies to evalu-
ate the effects of a supplement of marine protein hydrolysate (MPH) on measures of physical function
and strength. Eighty-six older adults received nutritional supplements containing 3 g of MPH or
a placebo for up to 12 months. Short Physical Performance Battery (SPPB), grip strength and gait
speed were measured, and dietary intake was registered at baseline, 6 months, and 12 months.
No difference was found between the intervention and control groups in mean change in SPPB
(independent sample t-test, p = 0.41) or regarding time trend in SPPB, grip strength, or gait speed
(linear mixed model). The participants in our study were well functioning, causing a ceiling effect in
SPPB. Further, they had sufficient protein intake and were physically active. Differences in physi-
cal function between those completing the intervention and the dropouts might also have created
bias in the results. We recommend that future studies of MPH be carried out on a more frail or
malnourished population.
Keywords: hydrolysate; fish protein; ageing; physical function; dietary assessment; seafood intake;
healthy ageing
1. Introduction
In 2019, 65-year-old Norwegian men could expect to live five years longer compared
with 30 years ago [1]. With increasing lifespans, healthy ageing is crucial to maintain
independence and reduce future healthcare costs for society. Maintenance of muscle
strength and function plays an important role in healthy ageing [2]. Age-related muscle
wasting (i.e., sarcopenia) is accompanied by loss of strength and can compromise the
functional abilities and activity levels of the elderly [3,4].
One of the main mechanisms of muscle wasting is a reduction in muscle protein
synthesis (MPS), and it appears that the muscles of older adults are more resistant to
anabolic stimuli than the muscles of younger people. This implies that older muscles
might need larger amounts of protein than younger ones to adequately stimulate MPS [2,3].
However, high protein intake might be challenging as ageing is often accompanied by
decreased energy intake and loss of appetite, i.e., the anorexia of ageing [5].
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Protein supplements have been shown to elicit gains in muscle strength in older
people when used in combination with strength exercise [6]. However, the majority of
muscle wasting happens in periods of low physical activity [7]. Thus, it is also interesting
to study nutritional interventions alone, i.e., without combining them with exercise. Sev-
eral signaling pathways are described where proteins, peptides, and amino acids stimulate
MPS, and among the single amino acids, leucine and other branch-chained amino acids
(BCAA) are especially active parts of these pathways [8]. Lean fish is a source of protein
of good quality and tends to have a moderate to high content of BCAA [9]. Fish protein
supplements in small doses have shown a positive effect on body composition in favor of
muscle vs. fat in overweight people, both in a study using 3 g fish protein [10] and 1.4–2.8
g fish protein hydrolysate [11]. These doses are small, and the effect might be related to
bioactive peptides, rather than the known effect of protein as a source of amino acids [12].
Small dose supplements could constitute a more feasible way of supplementing elderly
and/or frail persons as the amount of intake is smaller and contributes less to the feeling
of satiety; thus, it does not suppress micronutrient intake from other food sources. The aim
of this trial was to evaluate the effects of marine protein hydrolysate (MPH) supplements
on physical function and strength in the elderly. This is one of the first long-term studies of
MPH and age-related changes in muscle health [12].
Our hypothesis was that a daily intake of 3 g MPH for 6 to 12 months would prevent
loss of physical performance, compared with a placebo, as measured by the Short Physical
Performance Battery (SPPB) and loss of muscle strength as measured by grip strength.
2. Results
The mean age of the participants in this study was 72.7 (SD 8.2) years: 72.5 (SD 8.3)
and 73.1 (SD 8.2) years in women and men, respectively. Forty participants (46.5%) had
higher education, and 30 participants (34.9%) lived alone. Forty-two participants (48.8%)
reported that they performed strength exercises at least once a week, and 45 participants
(52.3%) reported being physically active daily.
The mean protein intake was 71.8 g (SD 23.6) and 83.7 g (SD 19.0), corresponding
to 1.1 g/kg BW (SD 0.4) and 1.0 g/kg BW (SD 0.2) in women and men, respectively.
Energy intake was 1728 kcal (SD 542) in women and 1958 kcal (SD 498) in men.
The mean baseline values of SPPB were 10.5 points (SD 2.4): 10.3 points (SD 2.6) and
11.0 points (SD 1.8) in women and men, respectively. The top SPPB score of 12 points
was reached by 44 participants (51.2%). The mean baseline value of grip strength was
33.0 kg (SD 11.6): 26.7 kg (SD 6.7) and 45.5 kg (SD 8.4) in women and men, respectively.
Nine women (15.8%) had a grip strength <20 kg, and two men (6.9%) had a grip strength
<30 kg. The mean baseline gait speed was 1.0m/s (SD 0.3) in both women and men.
Characteristics of the participants in the intervention group and control group are
shown in Table 1, including intake of energy, protein, and seafood, levels of 25-hydroxy vita-
min D, outcome measures of physical function, and compliance with intervention/control.
At the 6-month follow-up, 26 participants reported gastrointestinal problems related
to the tablets, in the form of increased gas or slight nausea, constipation or diarrhea. Further,
26 participants reported some difficulties swallowing the tablets. However, these problems
were apparent in both the intervention and control groups (gastrointestinal symptoms
p = 0.64 and swallowing difficulties p = 0.11), and mean compliance of tablet intake from
the start to 6 months was 83.4% (SD 23.3). No compliance differences were found between
intervention group and control group (p = 0.97).
During the study, nine participants were lost before the 6-month follow-up, and an
additional 29 were lost between 6 and 12 months. The participants dropped out for
the following reasons: gastrointestinal problems related to tablets (n = 9), health issues
not related to the study (n = 4), lack of motivation due to the large number of tablets,
no experience of effect, or just ‘had enough’ (n = 10). Three participants developed illnesses
listed as exclusion criteria during the study. As illustrated in Table 2, dropouts were older
(p = 0.01), had lower physical function (SPPB p = 0.01 and gait speed p< 0.001) and strength
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(p = 0.01). Additionally, dropouts more often lived alone compared with participants
completing the study (p = 0.03). However, there were no differences in energy, protein,
or seafood intake between dropouts and participants completing the study.
According to the primary analysis based on independent samples t-test, there was
no significant difference in mean change between intervention and control groups in the
main outcome, SPPB, from baseline to 12 months (p = 0.41). However, this analysis does
not adjust for differences in the cluster effect within each municipality, which was found
to be of significance with ICC 88.7%, 37.0%, and 62.3% for SPPB, grip strength, and gait
speed, respectively. Particularly, the participants recruited from homecare services were
very distinct from the others.
Table 1. Demographic and clinical characteristics at the baseline, and descriptive statistics of the
outcome variables of the randomized participants (N=86) at each time point, in the intervention
(n = 43) * and control (n = 43) * groups.
Intervention Control
Demographic and clinical characteristics
Demographic:
Age in years, mean (SD) 73.4 (8.7) 72.0 (7.7)
Weight, kg mean (SD) 72.2 (13.1) 78.5 (14.7)
BMI, kg/m2 mean (SD) 25.5 (3.8) 27.7 (4.7)
Gender, female, n (%) 29 (67.4) 28 (65.1)
Education level college/university, n (%) 21 (48.8) 19 (44.2)
Perform strength exercise weekly, n (%) 22 (51.2) 20 (46.5)
Other physical activities daily, n (%) 28 (65.1) 17 (39.5)
Live alone, n (%) 16 (37.2) 14 (32.6)
Dietary factors
Energy intake, kcal, mean (SD) 1809 (551) 1802 (527)
Energy intake, kcal/kgBW 1, mean (SD) 26.4 (8.8) 25.2 (8.8) a
Protein intake, g/kgBW 1, mean (SD) 1.1 (0.3) 1.1 (0.4) a
Protein intake, g/1000 kcal, mean (SD) 42.3 (10.4) 43.5 (10.1)
Seafood index 2, mean (SD) 3.3 (1.4) a 3.4 (1.2)
Serum 25-hydroxy vitamin D, nmol/L,
mean (SD) 84.2 (31.3)
c 84.1 (31.8) b
Outcome variables
SPPB 3, total points, mean (SD)
baseline 10.7(2.3) 10.4 (2.4)
6 months 11.0 (2.1) d 11.0 (1.6) c
12 months 11.4 (1.8) f 11.1 (1.8) g
Grip strength, kg, mean (SD)
baseline 33.0 (11.4) 33.1 (11.9)
6 months 34.2 (12.6) d 34.1 (10.6) b
12 months 37.0 (11.5) f 33.9 (10.9) g
Gait speed, m/s, mean (SD)
baseline 1.1 (0.3) 1.0 (0.3)
6 months 1.0 (0.3) d 1.0 (0.2) c
12 months 1.1 (0.2) f 1.1 (0.2) g
Compliance
% of tablets taken, 0–6 months (SD) 83.5 (23.1) 83.4 (23.8)
% of tablets taken, 6–12 months (SD) 92.1 (18.4) 92.9 (5.8)
Difficulties swallowing tablets n (%) 16 (29.7) d 10 (25.6) c
Gastrointestinal effects of tablets n (%) 11 (32.4) e 15 (37.5) b
1 BW = body weight, adjusted for over- and underweight. 2 Seafood index is computed from frequency questions
regarding seafood for dinner and lunch, and it corresponds to dinner portion equivalents per week. 3 Short Physi-
cal Performance Battery. * Variables with missing values are marked with remaining n: a n = 42, b n = 40, c n = 39,
d n = 37, e n = 34, f n = 28, g n = 20.
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Table 2. Baseline characteristics of, and p-value for difference between, participants completing the
12-month follow-up (n = 48) and participants dropping out (n = 38).
Completing Drop-Out p-Value
Age in years, (mean ± SD) 70.5 (6.3) 75.5 (9.5) 0.01 2
Female gender, n (%) 28 (58.3) 29 (76.3) 0.08 3
Living alone, n (%) 12 (25.0) 18 (47.4) 0.03 3
Education level
college/university, n (%) 27 (56.3) 13 (34.2) 0.04
3
Intervention group, n (%) 28 (58.3) 15 (39.5) 0.08 3
Control group, n (%) 20 (41.7) 23 (60.5) 0.08 3
Nutrition
Protein intake, g/kgBW 1 1.1 (0.4) 1.1 (0.3) 0.98 2
Energy intake, kcal/kgBW 1 25.9 (10.2) 25.8 (6.6) 0.98 2
Seafood intake, index 3.5 (1.3) 3.2 (1.2) 0.38 2
Physical function
SPPB, points (mean ± SD) 11.2 (1.5) 9.7 (3.0) 0.01 2
Grip strength, kg (mean ± SD) 35.7 (11.2) 29.6 (11.3) 0.01 2
Gait speed, m/s (mean ± SD) 1.1 (0.3) 0.9 (0.3) <0.001 2
1 BW = body weight, adjusted for over- and underweight. 2 p-value for independent samples t-test. 3 p-value for
χ2-test.
According to a bivariate linear mixed model for SPPB adjusting for a cluster effect
on a municipal level, there was no overall difference between the intervention group and
control group regarding time trend in SPPB, grip strength, or gait speed (non-significant
interactions) (Table 3). The intervention and control groups were, however, significantly
different in SPPB at the baseline (p = 0.033) and 6-month follow-up (p = 0.037), but not
at the 12-month follow-up (p = 0.093). For grip strength, groups were not significantly
different at any time point. Regarding gait speed, groups were significantly different at the
baseline (p = 0.027) and 6-month follow-up (p = 0.027), but not at the 12-month follow-up
(p = 0.106). These results are illustrated with 95% confidence intervals in Figure 1.
Table 3. Results of linear mixed models assessing changes in Short Physical Performance Battery (SPPB), grip strength, and gait speed
in relation to the intervention or control group. Adjusted for a cluster effect on a municipal level.
SPPB Grip Strength Gait Speed
N = 196 (n = 85 at T0, n = 68 at T6, n = 43 at T12) N = 197 (n = 85 at T0, n = 68 at T6, n = 43 at T12) N = 196 (n = 85 ved T0, n = 68 ved T6, n = 43 ved T12)
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ments of vitamin D. Thus, vitamin D was also excluded as an adjustment covariate. The 
results of the multiple linear mixed model reduced by Akaike’s Information Criterion did 
not change the conclusions of the bivariate analyses. 
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3. Discussion
Our intervention study among elderly persons did not reveal any significant differ-
ences in measures of physical function (SPPB and gait speed) or strength (grip strength)
between the intervention group receiving a supplement of MPH and the control group
receiving a placebo. However, the study participants had good physical function and
strength and sufficient protein intake at the starting point. We used standardized mea-
surements and questions to collect data at several time points, ensuring comparability of
results across different studies.
Mean SPPB in this study was 10.3 points in women and 11.0 points in men. In the
power calculation, we anticipated the mean SPPB to be 7.5 (see methods Section 4.7).
Our assumption was based on data from a more sedentary and already frail population [14]
as the initial goal was to recruit participants among home care service users. The SPPB
scores observed in our study were more in line with the normative scores reported by
Bergland et al. [15], where the mean score in the age group of 70–74 years was 10.8 in
women and 11.4 in men. Bergland’s study also reports that the SPPB test has a considerable
ceiling effect, where more than 20% have the highest or lowest scores. In our study, 51.2% of
the participants reached the top score of 12 points. Thus, the ceiling effect of the SPPB test
is a considerable shortcoming of our study as possible changes in physical function could
not be identified by our primary outcome measure.
The baseline values of the secondary outcomes, grip strength and gait speed, fur-
ther underline that the participants in our study sample have good physical function and
strength. The mean grip strength in our study was 26.7 kg in women and 45.5 kg in men.
Compared with the normative data reported by Dodds et al., this represents a level of grip
strength comparable to 60-year-old women and men [16]. However, all participants in
our study were >65years, with a mean age of 72.7 years. Recent studies in Norway [17]
and Finland [18] show that older adults are stronger and have better grip strength now
than in earlier generations, corresponding to a five-year difference, i.e., the more recently
born generation of 80-year-olds have a similar mean grip strength as 75-year-olds born one
generation earlier [17].
The participants in our study had a protein intake of 1.1 g/kg BW, which is higher
than the recommended daily allowance (RDA) of 0.8 g/kg and in accordance with the
increased dosage for elderly persons according to Nordic nutritional recommendations [19].
Protein intake is, however, lower than in other Norwegian studies such as Norkost3 [20]
and the Tromsø study [21]. Energy intake in our study was in line with the results of
Norkost3 in women; however, the male participants in our study reported lower energy
intake compared with Norkost3. This might indicate underreporting, especially by men.
Protein and energy intake were, however, assessed by a single day food recall, and this is a
weakness as diet often varies from day to day. Protein and energy intake were not included
in the regression model. However, their sufficient protein intake might indicate that this
study population was not the appropriate target group for MPH supplementation.
Moreover, the participants in our study had a relatively high seafood intake. The mean
computed seafood index corresponded to >3 meals of seafood per week, which is in accor-
dance with the dietary guidelines in Norway [22] and in line with data from Norkost3 [20].
The seafood intake was equally high in both intervention and control groups, and thus
would not influence the results in terms of difference between groups. However, the rela-
tively high seafood intake and protein intake among the participants might indicate that
they were not in need of supplementation, and thus it was difficult to notice any effects.
We anticipated that the SPPB score would decline by 0.9 points in the control group.
However, we could not detect a change in physical function over time in either the control
or intervention group. Bergland et al. [15] demonstrated that a decline in physical function,
as measured by the SPPB, occurs in the mid-sixties, with a slightly earlier decline in women
than in men. However, Hämäläinen [23] examined 6-year changes in physical performance
among high-functioning older adults and found improvement in physical performance in
age groups comparable to the participants in our study. Hämäläinen finds that this might
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be related to an increased physical activity level after recent retirement from work. In our
study, more than 50% reported being physically active daily. Weekly strength exercise was
also frequently reported. However, only self-reported frequency of physical activity and
strength exercise was measured, not the loading or the level of activity. Strength exercise
might be the most influential factor in muscle health in ageing, and nutritional supplements
may support these effects [24]. We wanted to examine the effects of the MPH supplement
without exercise; however, the possible high frequency of strength exercise in the group
might have biased the results.
Daily physical activity was more frequent in the intervention group than in the
control group, and the intervention and control groups were also significantly different
in SPPB and gait speed at the baseline and the 6-month follow-up, with higher scores in
the intervention group according to linear mixed model analyses adjusting for a cluster
effect on a municipal level. Groups were not significantly different at the 12-month follow-
up. Thus, differences between the intervention and control groups decreased with time;
however, this could be related to selection bias as dropouts were significantly different
from those completing the full 12-month follow-up.
Participants dropping out of the study had significantly lower scores in SPPB,
grip strength, and gait speed compared with those completing the follow-up. A review
of attrition in longitudinal studies among the elderly shows that dropout is associated
with, e.g., higher age, fewer years of education, poor functioning, and living alone [25].
These factors are also significantly different between participants dropping out versus
those completing our study. However, dietary factors did not significantly differ between
dropouts and those completing the study, nor did compliance in intervention or problems
related to the tablets. Compliance was high in both the intervention group and control
group, despite many reported problems with swallowing and/or gastrointestinal effects
related to the tablets. One out of three participants experienced gastrointestinal problems,
and every fourth participant had difficulties swallowing the tablets. As there were no
differences in gastrointestinal complaints or swallowing difficulties between the interven-
tion group and control group, we believe that the problems might be related to the large
number of tablets and possibly to the additives used to make the tablets look similar and
be odor free.
This study did not identify differences in measures of physical performance and
strength between the intervention group and control group; however, this might be related
to the limitations of the study. As previously discussed, the study participants had good
physical function, strength, and nutrient intake, and we could not see a decline in physical
function during the study. This might indicate that they were not in need of a supplement
enhancing MPS. On the other hand, one year might not be sufficient time to detect the
preventive effect on muscle health. This was one of the first studies assessing MPH in
relation to physical function and strength in older adults [12], and we suggest the following
recommendations for future studies:
- Future studies should be performed on a frailer population or on populations with
immobilized older adults. The population that is most in need of help with stimu-
lating MPS is composed of people who are immobilized over a period of time, e.g.,
after injuries or illnesses affecting mobility.
- MPH might have the potential to mitigate loss of muscle function and strength in
populations of older adults with lower protein and seafood intake.
- Physical activity should be measured more precisely.
- The large number of tablets was burdensome and might have caused gastrointestinal
symptoms in both the intervention and control groups. The number of tablets should
be reduced. The use of a soft drink, similar to the supplement used in the feasibility
study by Drotningsvik et al. [26], might be a better choice. Alternatively, MPH could
be used as an additive in enteral nutrition solutions or soft drink supplements.
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4. Materials and Methods
This study was a randomized, controlled, double-blinded trial in which the partici-
pants received tablets containing 3 g of MPH or a placebo, with data collected at a baseline
and at 6- and 12-month follow-ups. A 12-month follow-up period was planned for all
participants; however, they were given the supplements for 6 months at a time, with the
opportunity to withdraw at any time. Thus, statistical analyses were pre-planned to in-
clude measurements at both 6 months and 12 months of intervention. The study design is
graphically illustrated in Figure 2.
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4.1. Recruitment
Participants were recruited from March 2017 to May 2018, with all follow-up observa-
tions completed in January 2019. The study included adults ≥65 years old. Exclusion cri-
teria included active cancer or progressive muscle illness (e.g., multiple sclerosis or Lou
Gehrig’s disease), diabetes, kidney failure, short life expectancy (<1 year), and allergies to
fish protein. Mental illness or neurodegenerative illnesses were not defined as exclusion
criteria, however; participants were considered competent enough to provide informed
consent to participate. Initially, one of the inclusion criteria was need of home care ser-
vices, and recruitment was supposed to be facilitated trough municipal healthcare services.
However, this recruitment proved difficult, and after 6 months and only 16 participants
recruited, we omitted the criterion of the need for municipal support and started recruit-
ment through local media and by leaving flyers at healthcare offices and senior citizen
associations. A total of 92 individuals from several municipalities on the west coast of
Norway consented to participate in the study. They represented a mixed cohort of elderly
receiving home care services (n = 16) and elderly who were independent in daily activities
and thus were without need of municipal home care (n = 76). The predetermined sample
size goal of 82 (see power calculation below) was achieved, however, we did not succeed in
recruiting extra participants to account for dropouts. The flow of participant recruitment
and allocation is described in Figure 3 (CONSORT flow diagram).
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4.2. Randomisation
Eight participants withdrew their consent, and one was excluded due to exclusion
criteria occurring after inclusion, leaving 86 participants, 57 women and 29 men for ran-
domization into the intervention group (n = 43) or control group (n = 43).
The participants were given project identification numbers and block-randomized into
two groups. Blocks were based on the baseline score of the SPPB test (low score 0–6 points,
medium score 7–9 points, or high score 10–12 points) and gender. The main researcher
(LKN) enrolled participants and forwarded identification numbers and block information
to the statistician (JSB), who performed randomization into either group A (n = 43) or
group B (n = 43). Supplements and placebos were distributed in similar boxes prepared
by a person not involved in the study and only marked with participants’ identification
numbers. Participants, care providers, outcome assessors, and data analysts were blinded
for the intervention. The study investigators were blinded when analyzing the primary
and secondary outcomes as the code was masked until statistical analyses were completed.
4.3. Intervention
The participants in both the intervention and control groups were instructed to take
five tablets twice a day, preferably with breakfast and their evening meal. For the inter-
vention group, each tablet contained 300 mg of MPH, which corresponds to a total dose
of 3 g of protein per day (1.5 g in the morning and 1.5 g in the evening). The tablets were
produced by Flexipharma AS and based on the marine peptide compound 565952 P from
Firmenich Bjørge Biomarin AS (data sheet in Supplemental Material). The marine peptide
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compound was manufactured through the hydrolysis of fresh or fresh-frozen Atlantic
cod fillet (Gadus morhua) using industrial food approved non-GMO proteolytic enzymes,
and maltodextrin from corn was added to mask the odor and taste of fish. Hydrolysis
was conducted using equipment and procedures according to regulations provided by the
Norwegian Food Safety Authorities. Marine peptides are approved as a food ingredient
in Norway according to EU regulations. The control group received the same number of
similar-looking placebo tablets produced from gum Arabic.
4.4. Assessments
Assessments were completed in the participants’ homes at the baseline and at 6- and
12-month follow-ups. The researcher filled in the questionnaires based on a structured
interview with each participant. Demographic data included age, gender, living con-
dition, and educational level, and this information was collected only at the baseline.
The participants’ education levels were dichotomized as having higher or lower education.
Higher education was defined as education at university or college level, i.e., more than
12 years of education.
Physical activity was reported in categories based on how often participants performed
strength exercises and how often they were physically active otherwise (e.g., walking,
running, bicycling). Strength exercise was dichotomized into at least once a week or more
seldom. Other physical activity was dichotomized into daily or more seldom.
A 24-hour food recall was conducted using a multiple pass method following the
five-step protocol described by Moshfegh et al. [27], recording all food items and amounts
eaten the day before the visit. To adapt the method to Norwegian participants, we used an
illustrated food portion booklet with a corresponding list of weights from the Norwegian
study Ungkost 2000 [28]. Energy and protein intake per day were calculated using the
online diet tool from the Norwegian Directorate of Health and the Norwegian Food Safety
Authority, www.kostholdsplanleggeren.no. The food database in the Diet Planner is based
on the Norwegian Food Composition table, which provides an overview of the content of
energy and nutrients for the most common foods eaten in Norway.
Estimated protein and energy intake were expressed in grams per kilogram (g/kg) of
body weight (BW). For participants who were under- or overweight (BMI < 22.0 kg/m2
or >27 kg/m2), the BW was adjusted by applying the BW corresponding to a BMI of
22 or 27 kg/m2, respectively. Higher BMI is recommended for older adults compared
with adults [29,30]. The BMI cut-off values used in this study are described in the Norwe-
gian guidelines for treatment and prevention of malnutrition [31]. This adjustment was
made to let the intake represent the intake related to protein requirement rather than BW
in under- and overweight individuals, as underweight persons require extra protein to
build muscle tissue, while the extra weight in overweight persons is often composed of
adipose tissue [32,33].
Habitual intake of seafood in the past 6 months was estimated by using a shorter
version of a previously validated Food Frequency Questionnaire (FFQ) [34]. The frequency
of seafood intake for dinner and frequency of seafood used as a spread in salads, as a snack,
or something similar was recorded. Responses were reported as never, <1 time/month,
1–3 times/month, once/week, 2–3 times/week, and ≥4 times/week. The midpoint of
categories was used to calculate frequency of meals per week, e.g., 2–3 times per week
was regarded as 2.5. Frequency of seafood used as a spread in salads, as a snack, or some-
thing similar was divided by six, as six portions of seafood as spreads correspond to
one dinner portion. Thus, the combined frequency of seafood consumption corresponds
to a dinner portion equivalent per week. This method of making a continuous scale
of seafood consumption from FFQ was developed and validated against biomarkers by
Markhus et al. [35].
Body mass was recorded in light clothing to the nearest 0.1 kg using a digital scale (Seca
803), and height was measured with a tape measure (Seca 201). Furthermore, the partici-
pants were instructed to visit their general practitioner (GP) for blood sampling. Blood sam-
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ples were handled at the participants’ local municipality laboratories, and serum was
sent to the local hospital for analysis of 25-hydroxy vitamin D as a biomarker for vitamin
D status.
4.5. Main Outcome: Short Physical Performance Test (SPPB)
Muscle performance was measured with the SPPB, a test battery developed originally
for the Established Populations for Epidemiologic Studies of the Elderly and translated into
Norwegian in 2013 by Bergh and colleagues [36]. The test battery includes standing bal-
ance, walking speed, and repeated chair rise. Each of the three domain scores ranges from
0–4 points, yielding an integer sum score ranging from 0–12 points. A higher sum score
indicates a higher level of functioning, and a change of one unit is considered a clinically
meaningful change [14]. A systematic review of instruments assessing performance-based
physical function in older community-dwelling persons concluded that the SPPB is highly
recommended in terms of validity, reliability, and responsiveness [37]. The SPPB comple-
ments self-reported disability and may predict mortality and nursing home admission even
at the high end of the functional spectrum [38]. Gait speed was calculated as meters per
second (m/s) from the 4m walking test included in SPPB and used as a secondary outcome.
4.6. Secondary Outcome: Grip Strength
Grip strength was measured to the nearest 0.1 kg using the Jamar Plus+ digital hand
dynamometer. The maximum value of three trials on each hand was used for analyses [16].
Grip strength is a useful and simple measure of muscle strength. It correlates with leg
strength, is a clinical marker of poor mobility, and is considered a better predictor of clinical
outcomes than low muscle mass [39]. Cutoff scores are set at 30 kg and 20 kg for men
and women, respectively [39]. However, Dodds et al. provided normative data for grip
strength across the life course [16].
4.7. Sample Size and Statistical Power Calculation
Based on an American study reporting a clinically meaningful change in the main
outcome of SPPB to be 0.4–1.5 points [14], we assumed that the mean SPPB score at inclusion
was 7.52 in both groups, and the standard deviation after the intervention period would be
1.42 in both groups. Freiberger et.al. [37] evaluated the responsiveness of SPPB, and the
observed effect sizes in intervention studies were ranging from 0.48 to 1.25. Based on
these numbers, we assumed a reduction of 0.9 (mid-point) in the control group. We also
assumed that the intervention group maintained a stable SPPB score throughout the study
period, so that the effect would be seen as a decrease in the control group. A sample size
of 41 participants in each group was required to detect a statistically significant mean
difference of 0.9 points at a significance level of 5% and with a power of 80% using a two-
sided independent samples t-test. As the participants were older, we expected a 20%
dropout rate and therefore aimed to include 50 participants in each group.
4.8. Statistical Analyses
The demographic and clinical characteristics of the participants in each group were
described as means and standard deviations (SDs) or frequencies and percentages, as appro-
priate. Independent samples t-test and χ2-test were used to assess the gender differences
and differences between participants completing the study and the dropouts. As a primary
analysis, independent samples t-test was used to assess the difference in change in the
primary outcome, SPPB, between the intervention group and the control group.
A linear mixed model was then estimated to assess the effect of MPH on the SPPB in
the intervention group and control group throughout the 12-month follow-up. The model
included fixed effects for time components up to the second order to account for non-linear
effects, group allocation, and interaction between the two. A significant interaction between
time and group allocation would imply differences in SPPB scores between the groups
throughout the follow-up. As participants were recruited from different municipalities,
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the data will likely exhibit a hierarchical structure. The within-municipality cluster effect
was assessed using the intra-class correlation coefficient (ICC). Moreover, due to repeated
measurements for each participant, the within-participant correlation will likely be present.
Therefore, random effects for participants nested within the municipality were included
to correctly adjust estimates for possible within-participant and within-municipality cor-
relations. Random slopes for the time component were considered but not included as
they did not improve the model fit. Pairwise comparisons were conducted by deriving
individual time-point contrasts within each group with corresponding 95% confidence
intervals (CIs) and p-values, and the results were illustrated graphically. The results were
further adjusted for several of the pre-planned covariates: age, gender, education, liv-
ing status, strength exercise, and habitual seafood intake [40]. Some of the pre-planned
covariates were not included due to high correlations or many missing values. Cases with
missing values on one or more covariates were excluded from regression analysis. Akaike’s
Information Criterion, where the smaller value means a better model, was used to reduce
models for excessive adjustment variables. The secondary outcomes grip strength (kg) and
gait speed (m/s) were assessed in the same way. Statistical analyses were performed using
SPSS v 24 and SAS v 9.4. Results with p-values below 0.05 were considered statistically
significant. The intention-to-treat principle was used in statistical analysis.
4.9. Ethical Approval and Registration
All subjects gave their informed oral and written consent for inclusion before they
participated in the study, which was conducted in accordance with the Declaration of
Helsinki and approved by the Regional Committee on Ethics in Medical Research (REK)
in Mid-Norway in September 2016 with the registration ID 2016/1152. Changes in in-
clusion criteria were approved in August 2017. The study protocol has been published
elsewhere [40], and the trial was pre-registered at http://www.clinicaltrials.gov with the
unique identifier NCT02890290.
Supplementary Materials: The following are available online at https://www.mdpi.com/1660-339
7/19/2/62/s1, Data sheet marine peptides.
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